>Overall, not great, but not a total disaster. Albuferon will live at least until the Genotype 1 results come out in March.<
From a business standpoint, this trial merely had to not fail, and HGSI accomplished that. Whether Albuferon becomes a big-selling drug depends almost entirely on the geno-1 outcome in March. Regards, Dew ‹‹
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”